Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of rimegepant for acute treatment of migraine in children and adolescents
jRCT2031230579Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in migraine, migraine with aura and migraine without aura comparing Rimegepant with Placebo (2 arms). Primary endpoint: Pain freedom in adolescents at 2 hours. Started Apr 2024; status: recruiting.
02
Drugs
rimegepant
03
Conditions
migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on jRCT2031230579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230579.